Fig. 9. Tumour-infiltrating dCAR T cells exhibit enhanced proliferation, activation and improved memory-phenotype under chronic tumour antigen-stimulation in vivo.
a In vivo experimental layout. A total of 5 × 106 luciferase-expressing Raji cells mixed with Matrigel were intraperitoneally (i.p.) transferred to NPG mice. Tumour growth was monitored by bioluminescence (BLI). After 7 days, 1 × 106 dCAR T or CAR T cells were injected (i.v.) following the schedule shown. Tumours were obtained from five mice on sacrificed days 7 and 14 after cell infusion to measure tumour volume and isolate tumour-infiltrating dCAR or CAR T cells. b Cumulative data are shown the tumour burden of the mice, as assessed by tumour volume on days 0 and 14 (n = 5 mice examined over two independent experiments). Data are presented as the mean ± s.e.m. c The percentage of CAR T cells among the total number of MNC of the tumour (n = 4). d Expression of CD62L/CD45RO in tumour-infiltrating CD3-positive, CD4-positive and CD8-positive CAR T cells on days 7 and 14 after cell treatment (n = 4). e Expression of CD25 in tumour-infiltrating CAR T cells (n = 4). f Expression of PD1/TIM3/CD8 among tumour-infiltrating CAR T cells on days 7 and 14 after cell treatment (n = 4). The data in c–f are presented as the mean ± s.e.m. P values for c–f were calculated using a two-tailed unpaired t test.